News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,732 Results
Type
Article (43655)
Company Profile (473)
Press Release (693592)
Multimedia
Podcasts (122)
Webinars (20)
Section
Business (209305)
Career Advice (2038)
Deals (36150)
Drug Delivery (119)
Drug Development (83958)
Employer Resources (174)
FDA (16685)
Job Trends (15185)
News (354124)
Policy (33276)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2655)
Accelerated approval (34)
Adcomms (28)
Allergies (141)
Alliances (51111)
ALS (177)
Alzheimer's disease (1720)
Antibody-drug conjugate (ADC) (325)
Approvals (16921)
Artificial intelligence (534)
Autoimmune disease (150)
Automation (37)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (59)
Breast cancer (646)
Cancer (4894)
Cardiovascular disease (414)
Career advice (1723)
Career pathing (37)
CAR-T (287)
CDC (46)
Celiac Disease (2)
Cell therapy (768)
Cervical cancer (36)
Clinical research (71381)
Collaboration (1769)
Company closure (4)
Compensation (1168)
Complete response letters (62)
COVID-19 (2769)
CRISPR (96)
C-suite (855)
Cystic fibrosis (152)
Data (6261)
Decentralized trials (2)
Denatured (39)
Depression (141)
Diabetes (500)
Diagnostics (6734)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (259)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (241)
Earnings (91324)
Editorial (59)
Employer branding (21)
Employer resources (152)
Events (120932)
Executive appointments (993)
FDA (19810)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1515)
Gene editing (211)
Generative AI (44)
Gene therapy (636)
GLP-1 (1006)
Government (4753)
Grass and pollen (6)
Guidances (384)
Healthcare (19202)
HIV (57)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (270)
Immuno-oncology (58)
Indications (105)
Infectious disease (3033)
Inflammatory bowel disease (197)
Inflation Reduction Act (17)
Influenza (113)
Intellectual property (247)
Interviews (315)
IPO (16929)
IRA (52)
Job creations (3712)
Job search strategy (1439)
JPM (65)
Kidney cancer (15)
Labor market (83)
Layoffs (580)
Leadership (32)
Legal (8025)
Liver cancer (93)
Longevity (14)
Lung cancer (659)
Lymphoma (378)
Machine learning (43)
Management (59)
Manufacturing (798)
MASH (169)
Medical device (13908)
Medtech (13960)
Mergers & acquisitions (20288)
Metabolic disorders (1306)
Multiple sclerosis (164)
NASH (19)
Neurodegenerative disease (333)
Neuropsychiatric disorders (95)
Neuroscience (2998)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4580)
Now hiring (65)
Obesity (625)
Opinion (281)
Ovarian cancer (166)
Pain (204)
Pancreatic cancer (229)
Parkinson's disease (294)
Partnered (34)
Patents (492)
Patient recruitment (486)
Peanut (56)
People (60261)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22453)
Phase 2 (31472)
Phase 3 (23270)
Pipeline (5173)
Policy (294)
Postmarket research (2602)
Preclinical (9600)
Press Release (67)
Prostate cancer (243)
Psychedelics (55)
Radiopharmaceuticals (296)
Rare diseases (876)
Real estate (6064)
Recruiting (70)
Regulatory (24951)
Reports (51)
Research institute (2482)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (253)
Series B (197)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3803)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (81)
Vaccines (1014)
Venture capital (93)
Weight loss (406)
Women's health (89)
Worklife (19)
Date
Today (50)
Last 7 days (610)
Last 30 days (2054)
Last 365 days (30658)
2026 (2957)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (314)
Arkansas (14)
Asia (40672)
Australia (6759)
California (11388)
Canada (3277)
China (1128)
Colorado (481)
Connecticut (489)
Delaware (335)
Europe (89131)
Florida (1673)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (878)
India (63)
Indiana (519)
Iowa (24)
Japan (426)
Kansas (129)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1395)
Massachusetts (8284)
Michigan (322)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (33)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3031)
New Mexico (31)
New York (2983)
North Carolina (1520)
North Dakota (9)
Northern California (5526)
Ohio (334)
Oklahoma (21)
Oregon (45)
Pennsylvania (2281)
Puerto Rico (22)
Rhode Island (48)
South America (1121)
South Carolina (65)
South Dakota (1)
Southern California (4417)
Tennessee (173)
Texas (1753)
United States (40519)
Utah (339)
Vermont (1)
Virginia (264)
Washington D.C. (82)
Washington State (951)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
737,732 Results for "regulus therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novartis completes acquisition of Regulus Therapeutics
June 25, 2025
·
6 min read
Press Releases
Novartis announces expiration of Regulus Therapeutics tender offer
June 25, 2025
·
6 min read
Press Releases
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
May 27, 2025
·
9 min read
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for rare autosomal dominant polycystic kidney disease.
April 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
June 23, 2025
·
7 min read
Biotech Beach
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus Therapeutics Inc. “Regulus”), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. ET.
April 30, 2024
·
3 min read
Business
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Biotech Beach
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Inc. today announced the promotion of Rekha Garg , M.D., M.S., to Chief Medical Officer effective May 16, 2024.
May 16, 2024
·
4 min read
Biotech Beach
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Inc. announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors.
March 12, 2024
·
4 min read
Biotech Beach
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Regulus Therapeutics Inc. announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.
June 4, 2024
·
5 min read
1 of 73,774
Next
